Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063762 | 0.84 | HMGCR (0.31) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL4436457 | 0.84 | HMGCR (0.31) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL6747747 | 0.83 | THRB (0.31) | — | |
| SCHEMBL15060971 | 0.78 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL10024054 | 0.77 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL9269812 | 0.77 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL2067039 | 0.77 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL10024025 | 0.77 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL4440967 | 0.77 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL4643619 | 0.77 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513065-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2018-10-17 | — | — | EP | disclosed |
| EP-2134696-B1 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS (SI) | 2017-05-17 | — | — | EP | disclosed |
| EP-2134696-B1 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS (SI) | 2017-05-17 | — | — | EP | disclosed |
| US-9376397-B2 | Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2016-06-28 | — | — | US | disclosed |
| US-9376397-B2 | Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2016-06-28 | — | — | US | disclosed |
| US-9067895-B2 | Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-06-30 | — | — | US | disclosed |
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2015-05-21 | — | — | US | disclosed |
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2015-05-21 | — | — | US | disclosed |
| EP-2391609-B1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2015-01-28 | — | — | EP | disclosed |
| US-8471045-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-25 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-8183397-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2012-05-22 | — | — | US | disclosed |
| US-8183397-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2012-05-22 | — | — | US | disclosed |
| US-20120022091-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-01-26 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
| EP-2336116-A1 | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2011-06-22 | — | — | EP | disclosed |
| EP-2017267-A1 | Synthesis of statins | LEK Pharmaceuticals D.D. (SI) | 2009-01-21 | — | — | EP | disclosed |
| EP-1978020-A1 | Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof | LEK Pharmaceuticals D.D. (SI) | 2008-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, FDPS, SIRT5 | HMGCR 1/4885HDAC1 845/4885HDAC2 524/4885 |
| US-20110178295-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | HMGCR 1/4885HDAC1 1079/4885HDAC2 784/4885 |
| US-20120196333-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | HMGCR 1/4885HDAC1 1079/4885HDAC2 784/4885 |
| US-20120022091-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, FDPS, SIRT5 | HMGCR 1/4885HDAC1 845/4885HDAC2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.